title: [Primary sclerosing cholangitis].
abstract: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and obliteration of intra and/or extrahepatic bile ducts. The disease belongs to the most common cholestatic diseases in adults and at present is diagnosed with increasing frequency. It is very often associated with ulcerative colitis. Patients with PSC have an increased incidence of bile duct carcinomas and those with ulcerative colitis also have an increased incidence of colonic carcinomas. Immunosuppressive treatment is little effective. Ursodeoxycholic acid (UDCA) has been shown to improve liver histology in PSC. The aim is to treat patients as early as possible to prevent progression to the advanced stages of the disease. During treatment with UDCA stenoses of major ducts may develop and early endoscopic dilatation is highly effective. In patients with endstage disease, UDCA is not effective and liver transplantation is indicated.
authors.affiliation: Medizinische Universitätsklinik Heidelberg. adolf_stiehl@med.uni-heidelberg.de
authors.forename: A
authors.initials: A
authors.lastname: Stiehl
mesh_terms: D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D015209:Cholangitis, Sclerosing / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D015897:Comorbidity; D006801:Humans; D008111:Liver Function Tests; D011379:Prognosis; D012307:Risk Factors; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D014580:Ursodeoxycholic Acid